Navigation Links
Onconome Announces Results Of Blood Test For Colorectal Cancer; Further Trials Underway
Date:9/14/2012

REDMOND, Wash., Sept 14, 2012 /PRNewswire/ -- Onconome, Inc. today reported the results of studies on 431 patients based upon the blood test it has developed to determine an individual's probability of having colorectal cancer (CRC). The results of the studies have been published in the September issue of the "American Journal of Cancer Research" and demonstrate that Onconome's test is highly sensitive (93.75%) and specific (82.89%) to CRC and has a Negative Predictive Value of 99.9775% (NPV), meaning that a negative test result indicates an extremely low probability of a given patient having CRC. Onconome also reported that two additional clinical trials are now underway at three independent sites to further validate the test's efficacy as a CRC pre-screening tool.

The first of these trials (ONC04) is designed to evaluate blood samples from subjects who are 50 to 80 years old and therefore considered to be at elevated risk of CRC and who are scheduled for colonoscopy. Their samples will then be compared to their colonoscopy results to validate the test's sensitivity, specificity and NPV. The second trial (ONC05) includes patients who have already been diagnosed with CRC or pre-cancerous adenomas via colonoscopy or sigmoidoscopy and are scheduled for surgery. The endpoint of this trial is to establish the test's efficacy in detecting dangerous pre-cancerous conditions in the colon. Both trials are expected to be completed in 2013.

"It's an established fact that nearly half of adults age 50 or older have not had a colonoscopy in the past ten years and that relatively few use fecal occult blood test home kits," said Ray Cairncross, chief executive officer of Onconome. "A simple blood test which addresses these low compliance rates and provides both patients and their clinicians with an accurate assessment of an individual's risk of CRC would be an important tool in deciding whether to have a colonoscopy or sigmoidoscopy."

Onconome is a privately held clinical-stage company committed to the discovery and development of products focused on the early detection of colorectal cancer. See www.onconome.com.


'/>"/>
SOURCE Onconome, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Announces Management Change
2. Neuralstem Announces Proposed Public Offering
3. PPCE Announces Strategic Partnership With ECLINSO AG
4. Agendia Announces Five Studies in Breast Cancer for Presentation at the American Society of Clinical Oncology 2012 Breast Cancer Symposium
5. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
6. Soligenix Announces Issuance of US Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
7. Henry Schein Announces New $500 Million Credit Facility
8. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
9. Biodel Announces Phase 2 Clinical Trial Initiation Of Ultra-Rapid-Acting Insulin Candidate BIOD-123
10. Simcere Pharmaceutical Group Announces Appointment of New Chief Executive Officer
11. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
Breaking Medicine Technology:
(Date:6/26/2016)... Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in ... in honor of the city’s history as home to some of the world’s leading ...
(Date:6/26/2016)... ... ... a legally blind and certified personal trainer is helping to develop a weight loss fitness ... to fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
Breaking Medicine News(10 mins):